Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
Tissue microarray technology in breast cancer HER2 diagnostics
2007
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
High Concordance of SP3 Rabbit Monoclonal Antibody With FISH to Evaluate HER2 in Breast Carcinoma
2008
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
2007
External Quality Assurance of HER2 FISH and ISH Testing
2008
Standardization of HER2 testing: results of an international proficiency-testing ring study
2007
A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors
2005
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
2006
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
2013
Borderline HER‐2 breast cancer cases: Histochemical versus real‐time PCR analysis and impact of different cut‐off values
2007
Breast cancer
2019 Standout
Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
2016
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
2012
Gene amplification and overexpression of HER2 in renal cell carcinoma
2002
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
2010
Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer
2010
The Predictive Value of HER2 in Breast Cancer
2001
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
2008
Tissue microarray technology in the routine assessment of HER‐2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization
2008
Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas
2009
Triple-Negative Breast Cancer
2010 Standout
Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials
2001
Breast cancer
2016 Standout
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Tumor-Associated Macrophages in Breast Cancer
2002
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Determination ofHER2Amplification by In Situ Hybridization
2008
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
2004
Adjusting for Partial Verification or Workup Bias in Meta-Analyses of Diagnostic Accuracy Studies
2012
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification: Table 1
2011
HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
2003
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Protein tyrosine kinase inhibitors: new treatment modalities?
2002
Breast core needle biopsy: issues and controversies
2010
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases
2005
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
2010
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial
1996
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
2000
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
1997
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
2001 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
2010 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Intraoperative Electron Radiotherapy (IOERT) as an Alternative to Standard Whole Breast Irradiation: Only for Low-Risk Subgroups?
2014
Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Nanotheranostics for personalized medicine
2013
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
HeterogeneousHER2Gene Amplification
2011
Nano-magnetite (Fe3O4) as a support for recyclable catalysts in the development of sustainable methodologies
2013 Standout
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
2015
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
In situ cytokine production by breast cancer tumor-infiltrating lymphocytes
1996
The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer
2009
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
2015 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
2007
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Breast Cancer Treatment
2019 Standout
Graphene-Like Two-Dimensional Materials
2013 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
Automated Cellular Imaging System III for Assessing HER2 Status in Breast Cancer Specimens
2009
Metabolic reprogramming and cancer progression
2020 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
2015
Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus
2006
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Works of E. Mallon being referenced
Recommendations for HER2 testing in the UK
2000
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres
2003
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
2009
Assessment of HER2 status in breast cancer
2000
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
2013
Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer
1996
Breast-conserving surgery and tumour bed positivity in patients with breast cancer
1994
Molecular diagnostics for determination of HER2 status in breast cancer
2003
Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer
1990
Tumour bed positivity predicts outcome after breast-conserving surgery
1997
Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015)
2018
Optimum number of core biopsies for accurate assessment of histological grade in breast cancer
2002